ARA-290 (Cibinitide) Research & Studies
We track 20 published, PubMed-indexed studies for ARA-290 (Cibinitide), spanning 2012 to 2025. The research below includes 7 reviews, 10 research articles, 3 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
7
Reviews
10
Research Articles
3
Clinical Trials
Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.
ReviewSun Y, Song B, et al.|Front Neurol|2025
The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.
ReviewLiu G, Liang J, et al.|Int Immunopharmacol|2024
Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.
Research ArticleWang RL, Yang ZH, et al.|CNS Neurosci Ther|2024
Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways.
Research ArticleGhassemi-Barghi N, Ehsanfar Z, et al.|Inflammation|2023
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Research ArticleAl-Onaizi MA, Thériault P, et al.|Brain Behav Immun|2022
Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice.
Research ArticleDennhardt S, Pirschel W, et al.|Front Immunol|2022
A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.
Research ArticleWinicki NM, Nanavati AP, et al.|Front Cardiovasc Med|2022
The time to develop treatments for diabetic neuropathy.
ReviewRendell MS|Expert Opin Investig Drugs|2021
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region.
Research ArticleMohtavinejad N, Hajiramezanali M, et al.|Iran J Basic Med Sci|2021
ARA290 inhibits high glucose-induced apoptosis of NRK-52E cells.
Research ArticleZhao LJ, Sun XL, et al.|J Biol Regul Homeost Agents|2021
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.
Research ArticleShokrzadeh M, Etebari M, Ghassemi-Barghi N|Toxicol In Vitro|2020
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.
Research ArticleLois N, Gardner E, et al.|J Clin Med|2020
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand.
Research ArticleYao M, Watanabe M, et al.|Transplantation|2020
Managing fatigue in sarcoidosis - A systematic review of the evidence.
ReviewAtkins C, Wilson AM|Chron Respir Dis|2017
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Clinical TrialBrines M, Dunne AN, et al.|Mol Med|2015
Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
ReviewCollino M, Thiemermann C, et al.|Pharmacol Ther|2015
ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
Reviewvan Velzen M, Heij L, et al.|Expert Opin Investig Drugs|2014
Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events.
Reviewvan Rijt WG, van Goor H, et al.|Transpl Int|2014
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
Clinical TrialDahan A, Dunne A, et al.|Mol Med|2013
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Clinical TrialHeij L, Niesters M, et al.|Mol Med|2012